Key facts
- This page summarizes Harold Bernstein's Form 3 filing for Maze Therapeutics, Inc. (MAZE).
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 30 Jan 2025, 16:22.
Harold Bernstein - 30 Jan 2025 Form 3 Insider Report for Maze Therapeutics, Inc. (MAZE)
- Reporting relationship
- President, R&D & CMO
- Issuer ticker
- MAZE
- Reported as of
- 30 Jan 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 30 Jan 2025, 16:22:45 UTC
- Next SEC filing
- 24 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Courtney Phillips, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Harold Bernstein filed Form 3 for Maze Therapeutics, Inc. (MAZE) on 30 Jan 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MAZE
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 387,407
- Exercise price
- $10.42
- Footnotes
- F1
MAZE
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,930
- Exercise price
- $10.42
- Footnotes
- F2
MAZE
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 142,101
- Exercise price
- $10.42
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Footnote F2
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on April 1, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Footnote F3
The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.